Amniotics chairman Christer Fåhraeus was recently featured in Dagens Industri. The 25 million SEK that Amniotics now takes in venture capital will be enough to investigate the possibility of using the technology against Covid-19.
“We intended to use stem cells for a disease where the lung becomes inflammatory and fibrotic, but then came Covid-19 and it turns out to have a similar disease component with destroyed tissue and severe inflammation,” says Christer Fåhraeus, chairman and largest owner of the company.
https://www.di.se/nyheter/hoppas-bota-covidsjuka-med-stamceller-tar-in-25-miljoner/
